Natalizumab improves disability on the Multiple Sclerosis Functional Composite in a randomised, double-blind, placebo-controlled study of patients with relapsing multiple sclerosis

被引：0
|
作者：
Munschauer, F.
Giovannoni, G.
O'Connor, P. W.
Phillips, J. T.
Polman, C. H.
Pace, A.
Hyde, R.
Kim, R.
机构：
[1] Jacobs Neurol Inst, Buffalo, NY USA
[2] Barts & London Queen Marys Sch Med & Dent, London, England
[3] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[4] Multiple Sclerosis Ctr Texas Neurol, Dallas, TX USA
[5] VU Med Ctr, Amsterdam, Netherlands
[6] Biogen Idec Inc, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S124 / S125
页数：2
相关论文
共 50 条
  • [31] Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
    Wynn, Daniel
    Kaufman, Michael
    Montalban, Xavier
    Vollmer, Timothy
    Simon, Jack
    Elkins, Jacob
    O'Neill, Gilmore
    Neyer, Lauri
    Sheridan, James
    Wang, Chungchi
    Fong, Alice
    Rose, John W.
    [J]. LANCET NEUROLOGY, 2010, 9 (04): : 381 - 390
  • [32] HYPERBARIC-OXYGEN IN MULTIPLE-SCLEROSIS - A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY
    CONFAVREUX, C
    MATHIEU, C
    CHACORNAC, R
    AIMARD, G
    DEVIC, M
    [J]. PRESSE MEDICALE, 1986, 15 (28): : 1319 - 1322
  • [33] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis (vol 352, pg 1498, 1998)
    Ebers, GC
    McDougall, A
    Frith, J
    [J]. LANCET, 1999, 353 (9153): : 678 - 678
  • [34] A placebo-controlled, randomized, double-blind, MRI trial of antiherpes therapy in patients with relapsing-remitting multiple sclerosis (RRMS)
    Jakobsen, J
    Bech, E
    Gadeberg, P
    Hansen, HJ
    Christensen, T
    Haahr, S
    Hollsberg, P
    Lycke, J
    Malmestrom, C
    Ekholm, S
    Bergstrom, T
    Svennerholm, B
    Andersen, O
    [J]. NEUROLOGY, 2001, 56 (08) : A74 - A74
  • [35] Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study
    Filippi, M
    Wolinsky, JS
    Comi, G
    [J]. LANCET NEUROLOGY, 2006, 5 (03): : 213 - 220
  • [36] A randomised, double-blind, placebo-controlled trial of duloxetine for the treatment of central neuropathic pain associated with multiple sclerosis
    Vollmer, T.
    Robinson, M.
    Risser, R.
    Malcolm, S. K.
    Carlson, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S476 - S477
  • [37] The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial
    Amin, Sam
    Mallick, Andrew A.
    Edwards, Hannah
    Cortina-Borja, Mario
    Laugharne, Matthew
    Likeman, Marcus
    O'Callaghan, Finbar J. K.
    [J]. ECLINICALMEDICINE, 2021, 32
  • [38] Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial
    Johnson, KP
    Brooks, BR
    Cohen, JA
    Ford, CC
    Goldstein, J
    Lisak, RP
    Myers, LW
    Panitch, HS
    Rose, JW
    Schiffer, RB
    Vollmer, T
    Weiner, LP
    Wolinsky, JS
    [J]. NEUROLOGY, 2001, 57 (12) : S16 - S24
  • [39] A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis
    Rostami, AM
    Sater, RA
    Bird, SJ
    Galetta, S
    Farber, RE
    Kamoun, M
    Silberberg, DH
    Grossman, RI
    Pfohl, D
    [J]. MULTIPLE SCLEROSIS JOURNAL, 1999, 5 (03) : 198 - 203
  • [40] A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis
    Miller, AE
    Morgante, LA
    Buchwald, LY
    Coyle, PK
    Krupp, LB
    Doscher, CA
    Lublin, FD
    Knobler, RL
    Trantas, F
    Kelley, L
    Smith, CR
    LaRocca, N
    Lopez, S
    [J]. NEUROLOGY, 1997, 48 (02) : 312 - 314
12345